Blog

Interventions for visual field defects in patients with stroke

Abstract

Background

Visual field defects are estimated to affect 20% to 57% of people who have had a stroke. Visual field defects can affect functional ability in activities of daily living (commonly affecting mobility, reading and driving), quality of life, ability to participate in rehabilitation, and depression and anxiety following stroke. There are many interventions for visual field defects, which are proposed to work by restoring the visual field (restitution); compensating for the visual field defect by changing behaviour or activity (compensation); substituting for the visual field defect by using a device or extraneous modification (substitution); or ensuring appropriate diagnosis, referral and treatment prescription through standardised assessment or screening, or both.

Objectives

To determine the effects of interventions for people with visual field defects after stroke.

Search methods

We searched the Cochrane Stroke Group Trials Register, the Cochrane Eyes and Vision Group Trials Register, CENTRAL, MEDLINE, Embase, CINAHL, AMED, PsycINFO, and PDQT Databse, and clinical trials databases, including ClinicalTrials.gov and WHO Clinical Trials Registry, to May 2018. We also searched reference lists and trials registers, handsearched journals and conference proceedings, and contacted experts.

Selection criteria

Randomised trials in adults after stroke, where the intervention was specifically targeted at improving the visual field defect or improving the ability of the participant to cope with the visual field loss. The primary outcome was functional ability in activities of daily living and secondary outcomes included functional ability in extended activities of daily living, reading ability, visual field measures, balance, falls, depression and anxiety, discharge destination or residence after stroke, quality of life and social isolation, visual scanning, adverse events, and death.

Data collection and analysis

Two review authors independently screened abstracts, extracted data and appraised trials. We undertook an assessment of methodological quality for allocation concealment, blinding of outcome assessors, method of dealing with missing data, and other potential sources of bias. We assessed the quality of evidence for each outcome using the GRADE approach.

Main results

Twenty studies (732 randomised participants, with data for 547 participants with stroke) met the inclusion criteria for this review. However, only 10 of these studies compared the effect of an intervention with a placebo, control, or no treatment group, and eight had data which could be included in meta‐analyses. Only two of these eight studies presented data relating to our primary outcome of functional abilities in activities of daily living. One study reported evidence relating to adverse events.

Three studies (88 participants) compared a restitutive intervention with a control, but data were only available for one study (19 participants). There was very low‐quality evidence that visual restitution therapy had no effect on visual field outcomes, and a statistically significant effect on quality of life, but limitations with these data mean that there is insufficient evidence to draw any conclusions about the effectiveness of restitutive interventions as compared to control.

Four studies (193 participants) compared the effect of scanning (compensatory) training with a control or placebo intervention. There was low‐quality evidence that scanning training was more beneficial than control or placebo on quality of life, measured using the Visual Function Questionnaire (VFQ‐25) (two studies, 96 participants, mean difference (MD) 9.36, 95% confidence interval (CI) 3.10 to 15.62). However, there was low or very‐low quality evidence of no effect on measures of visual field, extended activities of daily living, reading, and scanning ability. There was low‐quality evidence of no significant increase in adverse events in people doing scanning training, as compared to no treatment.

Three studies (166 participants) compared a substitutive intervention (a type of prism) with a control. There was low or very‐low quality evidence that prisms did not have an effect on measures of activities of daily living, extended activities of daily living, reading, falls, or quality of life, and very low‐quality evidence that they may have an effect on scanning ability (one study, 39 participants, MD 9.80, 95% CI 1.91 to 17.69). There was low‐quality evidence of an increased odds of an adverse event (primarily headache) in people wearing prisms, as compared to no treatment.

One study (39 participants) compared the effect of assessment by an orthoptist to standard care (no assessment) and found very low‐quality evidence that there was no effect on measures of activities of daily living.

Due to the quality and quantity of evidence, we remain uncertain about the benefits of assessment interventions.

Authors’ conclusions

There is a lack of evidence relating to the effect of interventions on our primary outcome of functional ability in activities of daily living. There is limited low‐quality evidence that compensatory scanning training may be more beneficial than placebo or control at improving quality of life, but not other outcomes. There is insufficient evidence to reach any generalised conclusions about the effect of restitutive interventions or substitutive interventions (prisms) as compared to placebo, control, or no treatment. There is low‐quality evidence that prisms may cause minor adverse events.

Plain language summary

Interventions for visual field defects in people with stroke

Review question

Are there effective treatments for people who have visual field defects after stroke?

Background

Stroke can cause some people (20% to 57% of people with stroke) to lose the ability to see the entire space in front of them ‐ often one complete half of the normal field of vision is lost. These problems with seeing are called visual field defects. Visual field defects can make it difficult for people to function normally ‐ especially moving about freely, avoiding obstacles, reading, driving, and taking part in rehabilitation for other stroke‐related problems.

We wanted to see whether treatments for visual field defects could improve stroke survivors’ abilities in activities of daily living (our primary outcome of interest), or other (secondary) outcomes. Secondary outcomes that we were interested in included the size of the visual field defect, independence (in functional abilities), quality of life, ability to scan/search for objects, reading ability, balance and falls, depression and anxiety, and adverse events.

Study characteristics

We included 20 studies (involving 547 stroke participants) that investigated the effect of treatments for visual field defects. However, only 10 of these studies compared the effect of a particular treatment with no treatment. Three of these studies investigated a type of eye movement training designed to improve the lost visual field (a ‘restitutive’ intervention). Four of the included studies investigated the effect of scanning training, which involves training people to ‘scan’ across the space in front of them and into the ‘lost’ visual field, in order to better cope with their lost vision (a ‘compensatory’ intervention). Three of the included studies investigated the effect of wearing a special prism on a pair of glasses, which increases the amount a person can see on their affected side (a ‘substitutive’ intervention). One of the studies investigated the effect of specialised assessment by an orthoptist (a hospital‐based vision specialist), compared to standard care.

Search date

We searched for studies up to May 2018.

Key results

Only two studies presented data relating to how treatment can improve stroke survivors’ abilities in activities of daily living, and there was a lack of consistency across studies that limited our ability to draw clear conclusions. There was insufficient evidence to draw any conclusions about the effectiveness of restitutive interventions as compared to control. There was low or very low‐quality evidence that scanning training may help improve quality of life, but may have no effect on other outcomes (including adverse events). There was low or very‐low quality evidence that prisms may have an effect on ability to scan (look) for objects, but may cause a range of minor adverse events (particularly headache) and may have no effect on other outcomes. Limitations with the evidence meant that we could not draw any conclusions about the benefits of assessment interventions.

Quality of the evidence

The quality of the evidence was low to very low, and in general was insufficient to reach conclusions about the effects of interventions for people with visual field defects.

Authors’ conclusions

Implications for practice

There is limited low‐quality evidence that compensatory scanning training may improve an important outcome (quality of life) in patients with visual field defects following stroke, but further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. There is insufficient evidence to reach a conclusion about the impact of compensatory scanning training on other outcomes.

There is insufficient evidence to reach generalised conclusions about the benefits of visual restitution therapy (restitutive intervention), prisms (substitutive intervention), or assessment or screening interventions for patients with visual field defects after stroke. Prisms may cause a range of adverse events, particularly headache.

Implications for research

Specific implications for research, based on the findings of this review, are outlined below.

Are further randomised controlled trials (RCTs) required?

RCTs are required to determine the effect of:

  • compensatory scanning training compared to no treatment, placebo, or usual care;
  • restitutive interventions compared to no treatment, control, or placebo;
  • substitutive interventions compared to no treatment, control, or placebo;
  • assessment or screening interventions compared to standard care.

Such RCTs must:

  • have adequate power (i.e. with an appropriate power calculation undertaken based on existing trial evidence);
  • have adequate allocation concealment, blinding of outcome assessor, and intention‐to‐treat analysis;
  • clearly define trial participants, with particular care relating to the diagnosis and inclusion of patients with visual field defects or visual neglect, or both;
  • consider the severity of the visual field defect and plan subgroup analyses, where appropriate;
  • include measures of functional ability in activities of daily living;
  • collect and report data relating to adverse events;
  • report clear and usable data.

We recommend that future RCTs concentrate on answering the specific question relating to the effectiveness of interventions compared to control, placebo, no treatment, or usual care rather than comparisons with variations of the same ‘type’ or category of intervention, or comparisons of different doses, adjuncts to treatment, or modes of delivery. We believe that until such time as the benefits of interventions for visual field defects compared to control, placebo, no treatment, or usual care have been established (or refuted), it is not beneficial to compare the relative effects of different interventions. We recommend that future RCTs should include outcomes that are of importance to people affected by this problem, such as quality of life, confidence, and participation in social activities and relationships. We recommend that consensus is reached relating to the important outcome measures which all future trials of interventions for visual field defects in people with stroke should assess (i.e. a core outcome set), and that stroke survivors, carers, health professionals, and researchers are involved in developing this core outcome set.

A number of RCTs are currently ongoing. Once they are completed it will be important to update this review and to re‐evaluate the need for further RCTs of interventions for visual field defects.

Share
Comments Off on Interventions for visual field defects in patients with stroke
  • The review abstracts published on this site are the property of John Wiley & Sons, Ltd., and of the Cochrane Review Groups that have produced the reviews.
Share
Share